Sensei Biotherapeutics (SNSE) Competitors

$20.34 -0.74 (-3.50%)

As of 01:29 PM Eastern

SNSE vs. EDSA, CNTB, DERM, ASRT, and HURA

Should you buy Sensei Biotherapeutics stock or one of its competitors? MarketBeat compares Sensei Biotherapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Sensei Biotherapeutics include Edesa Biotech (EDSA), Connect Biopharma (CNTB), Journey Medical (DERM), Assertio (ASRT), and TuHURA Biosciences (HURA). These companies are all part of the "pharmaceutical products" industry.

How does Sensei Biotherapeutics compare to Edesa Biotech?

Edesa Biotech (NASDAQ:EDSA) and Sensei Biotherapeutics (NASDAQ:SNSE) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, valuation, analyst recommendations, media sentiment and dividends.

Sensei Biotherapeutics' return on equity of -83.59% beat Edesa Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Edesa Biotech	N/A	-163.57%	-52.54%
Sensei Biotherapeutics	N/A	-83.59%	-69.97%

Edesa Biotech has a beta of 1.26, suggesting that its share price is 26% more volatile than the broader market. Comparatively, Sensei Biotherapeutics has a beta of -0.18, suggesting that its share price is 118% less volatile than the broader market.

Edesa Biotech is trading at a lower price-to-earnings ratio than Sensei Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Edesa Biotech	N/A	N/A	-$7.19M	-$1.15	N/A
Sensei Biotherapeutics	N/A	N/A	-$21.08M	-$16.67	N/A

Edesa Biotech presently has a consensus price target of $5.00, suggesting a potential downside of 66.08%. Sensei Biotherapeutics has a consensus price target of $40.00, suggesting a potential upside of 96.63%. Given Sensei Biotherapeutics' higher probable upside, analysts clearly believe Sensei Biotherapeutics is more favorable than Edesa Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Edesa Biotech	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Sensei Biotherapeutics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

5.5% of Edesa Biotech shares are held by institutional investors. Comparatively, 10.5% of Sensei Biotherapeutics shares are held by institutional investors. 24.4% of Edesa Biotech shares are held by company insiders. Comparatively, 23.2% of Sensei Biotherapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Edesa Biotech had 2 more articles in the media than Sensei Biotherapeutics. MarketBeat recorded 3 mentions for Edesa Biotech and 1 mentions for Sensei Biotherapeutics. Sensei Biotherapeutics' average media sentiment score of 1.89 beat Edesa Biotech's score of 0.30 indicating that Sensei Biotherapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Edesa Biotech	Neutral
Sensei Biotherapeutics	Very Positive

Summary

Edesa Biotech beats Sensei Biotherapeutics on 6 of the 11 factors compared between the two stocks.

How does Sensei Biotherapeutics compare to Connect Biopharma?

Connect Biopharma (NASDAQ:CNTB) and Sensei Biotherapeutics (NASDAQ:SNSE) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, profitability, valuation, institutional ownership, dividends, risk and earnings.

Sensei Biotherapeutics' return on equity of -83.59% beat Connect Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Connect Biopharma	N/A	-114.89%	-94.01%
Sensei Biotherapeutics	N/A	-83.59%	-69.97%

Sensei Biotherapeutics has lower revenue, but higher earnings than Connect Biopharma. Connect Biopharma is trading at a lower price-to-earnings ratio than Sensei Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Connect Biopharma	$60K	2,405.87	-$55.48M	-$1.00	N/A
Sensei Biotherapeutics	N/A	N/A	-$21.08M	-$16.67	N/A

Connect Biopharma has a beta of -0.21, suggesting that its stock price is 121% less volatile than the broader market. Comparatively, Sensei Biotherapeutics has a beta of -0.18, suggesting that its stock price is 118% less volatile than the broader market.

Connect Biopharma currently has a consensus target price of $8.67, suggesting a potential upside of 239.34%. Sensei Biotherapeutics has a consensus target price of $40.00, suggesting a potential upside of 96.63%. Given Connect Biopharma's stronger consensus rating and higher probable upside, equities analysts clearly believe Connect Biopharma is more favorable than Sensei Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Connect Biopharma	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80
Sensei Biotherapeutics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Connect Biopharma had 12 more articles in the media than Sensei Biotherapeutics. MarketBeat recorded 13 mentions for Connect Biopharma and 1 mentions for Sensei Biotherapeutics. Sensei Biotherapeutics' average media sentiment score of 1.89 beat Connect Biopharma's score of -0.23 indicating that Sensei Biotherapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Connect Biopharma	Neutral
Sensei Biotherapeutics	Very Positive

58.7% of Connect Biopharma shares are owned by institutional investors. Comparatively, 10.5% of Sensei Biotherapeutics shares are owned by institutional investors. 22.6% of Connect Biopharma shares are owned by insiders. Comparatively, 23.2% of Sensei Biotherapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Connect Biopharma beats Sensei Biotherapeutics on 8 of the 15 factors compared between the two stocks.

How does Sensei Biotherapeutics compare to Journey Medical?

Sensei Biotherapeutics (NASDAQ:SNSE) and Journey Medical (NASDAQ:DERM) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, institutional ownership, valuation, profitability, media sentiment, earnings and dividends.

Sensei Biotherapeutics has a beta of -0.18, suggesting that its share price is 118% less volatile than the broader market. Comparatively, Journey Medical has a beta of 1.03, suggesting that its share price is 3% more volatile than the broader market.

Journey Medical has higher revenue and earnings than Sensei Biotherapeutics. Journey Medical is trading at a lower price-to-earnings ratio than Sensei Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sensei Biotherapeutics	N/A	N/A	-$21.08M	-$16.67	N/A
Journey Medical	$61.86M	2.75	-$11.43M	-$0.47	N/A

In the previous week, Journey Medical had 9 more articles in the media than Sensei Biotherapeutics. MarketBeat recorded 10 mentions for Journey Medical and 1 mentions for Sensei Biotherapeutics. Sensei Biotherapeutics' average media sentiment score of 1.89 beat Journey Medical's score of 0.00 indicating that Sensei Biotherapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Sensei Biotherapeutics	Very Positive
Journey Medical	Neutral

Sensei Biotherapeutics presently has a consensus target price of $40.00, suggesting a potential upside of 96.63%. Journey Medical has a consensus target price of $13.00, suggesting a potential upside of 109.07%. Given Journey Medical's stronger consensus rating and higher probable upside, analysts plainly believe Journey Medical is more favorable than Sensei Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sensei Biotherapeutics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Journey Medical	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

10.5% of Sensei Biotherapeutics shares are owned by institutional investors. Comparatively, 7.3% of Journey Medical shares are owned by institutional investors. 23.2% of Sensei Biotherapeutics shares are owned by company insiders. Comparatively, 15.0% of Journey Medical shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Sensei Biotherapeutics has a net margin of 0.00% compared to Journey Medical's net margin of -18.48%. Journey Medical's return on equity of -46.40% beat Sensei Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sensei Biotherapeutics	N/A	-83.59%	-69.97%
Journey Medical	-18.48%	-46.40%	-13.22%

Summary

Journey Medical beats Sensei Biotherapeutics on 10 of the 15 factors compared between the two stocks.

How does Sensei Biotherapeutics compare to Assertio?

Assertio (NASDAQ:ASRT) and Sensei Biotherapeutics (NASDAQ:SNSE) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, valuation, dividends, media sentiment, risk, profitability and institutional ownership.

Sensei Biotherapeutics has lower revenue, but higher earnings than Assertio. Assertio is trading at a lower price-to-earnings ratio than Sensei Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Assertio	$102.16M	1.48	-$30.38M	-$5.69	N/A
Sensei Biotherapeutics	N/A	N/A	-$21.08M	-$16.67	N/A

In the previous week, Assertio had 8 more articles in the media than Sensei Biotherapeutics. MarketBeat recorded 9 mentions for Assertio and 1 mentions for Sensei Biotherapeutics. Sensei Biotherapeutics' average media sentiment score of 1.89 beat Assertio's score of -0.22 indicating that Sensei Biotherapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Assertio	Neutral
Sensei Biotherapeutics	Very Positive

49.0% of Assertio shares are owned by institutional investors. Comparatively, 10.5% of Sensei Biotherapeutics shares are owned by institutional investors. 5.7% of Assertio shares are owned by company insiders. Comparatively, 23.2% of Sensei Biotherapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Assertio has a beta of 0.44, indicating that its stock price is 56% less volatile than the broader market. Comparatively, Sensei Biotherapeutics has a beta of -0.18, indicating that its stock price is 118% less volatile than the broader market.

Assertio currently has a consensus price target of $22.65, indicating a potential downside of 2.87%. Sensei Biotherapeutics has a consensus price target of $40.00, indicating a potential upside of 96.63%. Given Sensei Biotherapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Sensei Biotherapeutics is more favorable than Assertio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Assertio	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80
Sensei Biotherapeutics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Sensei Biotherapeutics has a net margin of 0.00% compared to Assertio's net margin of -34.94%. Assertio's return on equity of -38.72% beat Sensei Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Assertio	-34.94%	-38.72%	-13.32%
Sensei Biotherapeutics	N/A	-83.59%	-69.97%

Summary

Sensei Biotherapeutics beats Assertio on 8 of the 15 factors compared between the two stocks.

How does Sensei Biotherapeutics compare to TuHURA Biosciences?

Sensei Biotherapeutics (NASDAQ:SNSE) and TuHURA Biosciences (NASDAQ:HURA) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, valuation, risk, dividends, institutional ownership, media sentiment, profitability and analyst recommendations.

In the previous week, TuHURA Biosciences had 4 more articles in the media than Sensei Biotherapeutics. MarketBeat recorded 5 mentions for TuHURA Biosciences and 1 mentions for Sensei Biotherapeutics. Sensei Biotherapeutics' average media sentiment score of 1.89 beat TuHURA Biosciences' score of 0.65 indicating that Sensei Biotherapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Sensei Biotherapeutics	Very Positive
TuHURA Biosciences	Positive

TuHURA Biosciences is trading at a lower price-to-earnings ratio than Sensei Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sensei Biotherapeutics	N/A	N/A	-$21.08M	-$16.67	N/A
TuHURA Biosciences	N/A	N/A	-$30.05M	-$0.63	N/A

Sensei Biotherapeutics has a beta of -0.18, indicating that its stock price is 118% less volatile than the broader market. Comparatively, TuHURA Biosciences has a beta of -0.01, indicating that its stock price is 101% less volatile than the broader market.

Sensei Biotherapeutics presently has a consensus target price of $40.00, suggesting a potential upside of 96.63%. TuHURA Biosciences has a consensus target price of $9.00, suggesting a potential upside of 257.71%. Given TuHURA Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe TuHURA Biosciences is more favorable than Sensei Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sensei Biotherapeutics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
TuHURA Biosciences	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

Sensei Biotherapeutics' return on equity of -83.59% beat TuHURA Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sensei Biotherapeutics	N/A	-83.59%	-69.97%
TuHURA Biosciences	N/A	-182.40%	-117.49%

10.5% of Sensei Biotherapeutics shares are held by institutional investors. Comparatively, 0.6% of TuHURA Biosciences shares are held by institutional investors. 23.2% of Sensei Biotherapeutics shares are held by insiders. Comparatively, 0.2% of TuHURA Biosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Sensei Biotherapeutics beats TuHURA Biosciences on 7 of the 13 factors compared between the two stocks.

Get Sensei Biotherapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SNSE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SNSE vs. The Competition

Export

Metric	Sensei Biotherapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$27.26M	$3.40B	$6.30B	$12.46B
Dividend Yield	N/A	2.31%	2.79%	5.30%
P/E Ratio	-1.22	18.73	20.92	25.65
Price / Sales	N/A	294.61	551.58	76.73
Price / Cash	N/A	122.51	42.94	55.34
Price / Book	1.38	6.77	9.87	6.72
Net Income	-$21.08M	$24.11M	$3.55B	$333.73M
7 Day Performance	-14.38%	0.05%	-0.20%	0.40%
1 Month Performance	-29.12%	0.91%	1.48%	4.09%
1 Year Performance	199.16%	77.69%	41.00%	36.52%

Sensei Biotherapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SNSE Sensei Biotherapeutics	2.0899 of 5 stars	$20.34 -3.5%	$40.00 +96.6%	+195.7%	$27.26M	N/A	N/A	40	Positive News Upcoming Earnings
EDSA Edesa Biotech	1.5765 of 5 stars	$15.45 -4.1%	$5.00 -67.6%	+662.0%	$143.15M	N/A	N/A	20	Short Interest Increase
CNTB Connect Biopharma	2.9782 of 5 stars	$2.47 -0.4%	$8.67 +250.9%	+221.9%	$140.17M	$60K	N/A	110	Earnings Report Upcoming Earnings Analyst Revision
DERM Journey Medical	2.552 of 5 stars	$5.18 +1.2%	$13.00 +151.0%	-18.4%	$139.93M	$61.86M	N/A	90	News Coverage Earnings Report Gap Up
ASRT Assertio	1.7922 of 5 stars	$22.16 +2.5%	$19.90 -10.2%	+155.4%	$139.28M	$118.71M	N/A	20	News Coverage Earnings Report Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SNSE) was last updated on 5/14/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Sensei Biotherapeutics (SNSE) Competitors

SNSE vs. EDSA, CNTB, DERM, ASRT, and HURA

How does Sensei Biotherapeutics compare to Edesa Biotech?

Summary

How does Sensei Biotherapeutics compare to Connect Biopharma?

Summary

How does Sensei Biotherapeutics compare to Journey Medical?

Summary

How does Sensei Biotherapeutics compare to Assertio?

Summary

How does Sensei Biotherapeutics compare to TuHURA Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SNSE vs. The Competition

Sensei Biotherapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Sensei Biotherapeutics (SNSE) Competitors

SNSE vs. EDSA, CNTB, DERM, ASRT, and HURA

How does Sensei Biotherapeutics compare to Edesa Biotech?

Is EDSA or SNSE more profitable?

Which has more volatility and risk, EDSA or SNSE?

Which has higher valuation and earnings, EDSA or SNSE?

Do analysts rate EDSA or SNSE?

Do institutionals and insiders believe in EDSA or SNSE?

Does the media favor EDSA or SNSE?

Summary

How does Sensei Biotherapeutics compare to Connect Biopharma?

Is CNTB or SNSE more profitable?

Which has stronger valuation and earnings, CNTB or SNSE?

Which has more risk and volatility, CNTB or SNSE?

Do analysts recommend CNTB or SNSE?

Does the media refer more to CNTB or SNSE?

Do institutionals & insiders hold more shares of CNTB or SNSE?

Summary

How does Sensei Biotherapeutics compare to Journey Medical?

Which has more volatility & risk, SNSE or DERM?

Which has higher earnings & valuation, SNSE or DERM?

Does the media favor SNSE or DERM?

Do analysts recommend SNSE or DERM?

Do insiders and institutionals have more ownership in SNSE or DERM?

Is SNSE or DERM more profitable?

Summary

How does Sensei Biotherapeutics compare to Assertio?

Which has higher valuation & earnings, ASRT or SNSE?

Does the media prefer ASRT or SNSE?

Do institutionals & insiders hold more shares of ASRT or SNSE?

Which has more risk and volatility, ASRT or SNSE?

Do analysts prefer ASRT or SNSE?

Is ASRT or SNSE more profitable?

Summary

How does Sensei Biotherapeutics compare to TuHURA Biosciences?

Does the media prefer SNSE or HURA?

Which has better earnings & valuation, SNSE or HURA?

Which has more risk and volatility, SNSE or HURA?

Do analysts rate SNSE or HURA?

Is SNSE or HURA more profitable?

Do institutionals & insiders hold more shares of SNSE or HURA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SNSE vs. The Competition

Sensei Biotherapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools